- Increased time-to-treatment-failure was revealed in a real world study on tofacitinib’s effectiveness
- The study allowed patients who wouldn’t have been considered for RCT inclusion to be analysed
- “This underscores the potential for real-world evidence studies to uncover new evidence of efficacy that might have been missed by the original controlled trials.” – Vivek Rudrapatna, University of California San Francisco (first author)
Click here to read the source article
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.